Register to get unlimited Level 2

Merck to buy ArQule in $2.7bn cash deal

By Michele Maatouk

Date: Monday 09 Dec 2019

Merck to buy ArQule in $2.7bn cash deal

(Sharecast News) - Merck has agreed to buy biopharmaceutical group ArQule in a $2.7bn cash deal.
Under the terms of the transaction, which is expected to close in the first quarter of next year, Merck will pay $20 per share. The price represents a 100% premium to ArQule's closing share price on Friday.

ArQule is engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. Its clinical-stage pipeline consists of four drug candidates, all of which are in targeted, biomarker-defined patient populations.

Roger M. Perlmutter, president of Merck Research Laboratories, said: "ArQule's focus on precision medicine has yielded multiple clinical-stage oral kinase inhibitors that have novel and important properties.

"This acquisition strengthens Merck's pipeline with the addition of these strategic assets including, most notably, ARQ 531, a compelling candidate for the treatment of B-cell malignancies."

At 1305 GMT, ArQule shares were up 101% in pre-market trade at $19.41.


Email this article to a friend

or share it with one of these popular networks:

Top of Page